Ryan Wurz

Company: Amgen

Job title: Associate Scientific Director

Seminars:

Panel Discussion: Does Pan-RAS Hold the Future of Precision Medicine? Exploring Combination Potential & Targeting Novel Isoforms 9:00 am

What is the current scope and strides in developing pan-RAS inhibitors? What combination therapies should be deployed with pan-RAS and how can we inform this? What is the future of pan-RAS? Will it replace mutant-specific therapies?Read more

day: Day One

Learning from Sotorasib: From Mutant-Selective Covalent Inhibitors to Reversible Pan-KRAS Inhibitors 8:30 am

• How structural insights from KRAS G12C inhibitors guided the design of inhibitors of other oncogenic KRAS mutants • Pharmacological profiling of pan-KRAS inhibitors and demonstrations of pre-clinical efficacy • Insights on the tolerability of wild-type KRAS inhibition and the role of on- and off-state targeting Read more

day: Day One